Experts and national consultants' recommendations regarding management of patients treated for migraine with comorbid depression. Diagnosis. Therapeutic strategies. Part 2.
Zalecenia ekspertów i konsultantów krajowych dotyczące postępowania u pacjentów leczonych z powodu migreny ze współwystępującą depresją. Diagnoza. Strategie terapeutyczne. Część 2.
depression
migraine
Journal
Psychiatria polska
ISSN: 2391-5854
Titre abrégé: Psychiatr Pol
Pays: Poland
ID NLM: 0103314
Informations de publication
Date de publication:
31 Aug 2022
31 Aug 2022
Historique:
medline:
21
4
2023
pubmed:
19
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
Depressive disorders are currently diagnosed based on the ICD-10 and DSM-5 diagnostic criteria and include axial depressive symptoms and additional symptoms that must coexist for at least two weeks. Migraine is diagnosed based on the International Classification of Headache Disorders. It is generally divided into migraine with and without aura, and with regard to the frequency of attacks into episodic and chronic migraine. The therapeutic strategy in the treatment of depression is pharmacotherapy combined with psychotherapy, whereas in the treatment of migraine the strategy depends on the frequency of headache attacks (episodic migraine vs. chronic migraine) and comorbidities. A novelty is the introduction of monoclonal antibodies directed against CGRP or the receptor of CGRP. There are numerous reports which indicate specific usefulness of monoclonal antibodies that modify the action of CGRP in the treatment of migraine in people suffering from depression.
Identifiants
pubmed: 37074825
pii: 139596
doi: 10.12740/PP/OnlineFirst/139596
pii:
doi:
Substances chimiques
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Antibodies, Monoclonal
0
Types de publication
Guideline
Langues
eng
pol
Sous-ensembles de citation
IM